Factor analysis in predominantly severe COPD: Identification of disease heterogeneity by easily measurable characteristics

Respiratory Medicine

Volumn 107, Issue 12, 2013, Pages 1939-1947

  Postma, Dirkje S ^a   Anzueto, Antonio R ^b   Jenkins, Christine ^c   Make, Barry J ^d   Similowski, Thomas ^e   Östlund, Ollie ^f   Eriksson, Göran S ^g   Calverley, Peter M ^h  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF COLORADO   (United States)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f ASTRAZENECA R AND D   (Sweden)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Exacerbations; Factor analysis; Heterogeneity

Indexed keywords

ARTICLE; BLOOD PRESSURE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMORBIDITY; COUGHING; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; FACTORIAL ANALYSIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENETIC HETEROGENEITY; HEALTH STATUS; HUMAN; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEX DIFFERENCE; SLEEP DISORDER; SMOKING;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; EXACERBATIONS; FACTOR ANALYSIS; HETEROGENEITY;

ACUTE DISEASE; BODY MASS INDEX; BRONCHODILATOR AGENTS; FACTOR ANALYSIS, STATISTICAL; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS; SMOKING; VITAL CAPACITY;

EID: 84890313666     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2013.07.011     Document Type: Article

References (30)

1. C.D. Mathers, and D. Loncar Projections of global mortality and burden of disease from 2002 to 2030 PLoS Med 3 2006 e442
2. T. Vos, A.D. Flaxman, M. Naghavi, R. Lozano, C. Michaud, and M. Ezzati Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2012 2163 2196
3. D.M. Mannino, and A.S. Buist Global burden of COPD: risk factors, prevalence, and future trends Lancet 370 2007 765 773
4. A. Agusti, P.M. Calverley, B. Celli, H.O. Coxson, L.D. Edwards, and D.A. Lomas Characterisation of COPD heterogeneity in the ECLIPSE cohort Respir Res 11 2010 122
5. Global Initiative for Chronic Obstructive Lung Disease Global strategy for diagnosis, management, and prevention of COPD (2011 update) 2011 Available from: http://www.goldcopd.org/uploads/users/files/GOLD-Report-2011-Jan21.pdf
6. M.B. Drummond, N.N. Hansel, J.E. Connett, P.D. Scanlon, D.P. Tashkin, and R.A. Wise Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease Am J Respir Crit Care Med 185 2012 1301 1306
7. J.C. Hogg, and W. Timens The pathology of chronic obstructive pulmonary disease Ann Rev Pathol 4 2009 435 459
8. J.R. Hurst, J. Vestbo, A. Anzueto, N. Locantore, H. Mullerova, and R. Tal-Singer Susceptibility to exacerbation in chronic obstructive pulmonary disease N Engl J Med 363 2010 1128 1138
9. P.W. Jones Health status measurement in chronic obstructive pulmonary disease Thorax 56 2001 880 887
10. M.K. Han, A. Agusti, P.M. Calverley, B.R. Celli, G. Criner, and J.L. Curtis Chronic obstructive pulmonary disease phenotypes: the future of COPD Am J Respir Crit Care Med 182 2010 598 604
11. P.M. Calverley, W. Boonsawat, Z. Cseke, N. Zhong, S. Peterson, and H. Olsson Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Eur Respir J 22 2003 912 919
12. S.I. Rennard, D.P. Tashkin, J. McElhattan, M. Goldman, S. Ramachandran, and U.J. Martin Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial Drugs 69 2009 549 565
13. W. Szafranski, A. Cukier, A. Ramirez, G. Menga, R. Sansores, and S. Nahabedian Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Eur Respir J 21 2003 74 81
14. D.P. Tashkin, S.I. Rennard, P. Martin, S. Ramachandran, U.J. Martin, and P.E. Silkoff Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial Drugs 68 2008 1975 2000
15. T. Welte, M. Miravitlles, P. Hernandez, G. Eriksson, S. Peterson, and T. Polanowski Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 180 2009 741 750
16. P.W. Jones, F.H. Quirk, C.M. Baveystock, and P. Littlejohns A self-complete measure of health status for chronic airflow limitation. The St. George's respiratory questionnaire Am Rev Respir Dis 145 1992 1321 1327
17. B.F.J. Manly Multivariate statistical methods: a primer 1986 Chapman & Hall London, New York
18. C. Casanova, J.P. de Torres, A. Aguirre-Jaíme, V. Pinto-Plata, J.M. Marin, and E. Cordoba The progression of chronic obstructive pulmonary disease is heterogeneous Am J Respir Crit Care Med 184 2011 1015 1021
19. B.R. Celli, P.M. Calverley, S.I. Rennard, E.F. Wouters, A. Agusti, and N. Anthonisen Proposal for a multidimensional staging system for chronic obstructive pulmonary disease Respir Med 99 2005 1546 1554
20. P.R. Burgel, J.L. Paillasseur, D. Caillaud, I. Tillie-Leblond, P. Chanez, and R. Escamilla Clinical COPD phenotypes: a novel approach using principal component and cluster analyses Eur Respir J 36 2010 531 539
21. H.A. Kerstjens, P.L. Brand, P.M. de Jong, G.H. Koeter, and D.S. Postma Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group Thorax 49 1994 1109 1115
22. T.J. Clark Diurnal rhythm of asthma Chest 91 1987 137S 141S
23. Y. Oosterhoff, H.F. Kauffman, B. Rutgers, F.J. Zijlstra, G.H. Koeter, and D.S. Postma Inflammatory cell number and mediators in bronchoalveolar lavage fluid and peripheral blood in subjects with asthma with increased nocturnal airways narrowing J Allergy Clin Immunol 96 1995 219 229
24. R. Kessler, M.R. Partridge, M. Miravitlles, M. Cazzola, C. Vogelmeier, and D. Leynaud Symptom variability in patients with severe COPD: a pan-European cross-sectional study Eur Respir J 37 2011 264 272
25. D. Postma, A. Anzueto, P. Calverley, C. Jenkins, B.J. Make, and F.C. Sciurba A new perspective on optimal care for patients with COPD Prim Care Respir J 20 2011 205 209
26. D.W. Mapel, J.S. Hurley, F.J. Frost, H.V. Petersen, M.A. Picchi, and D.B. Coultas Health care utilization in chronic obstructive pulmonary disease: a case-control study in a health maintenance organization Arch Intern Med 160 2000 2653 2658
27. J.B. Soriano, G.T. Visick, H. Muellerova, N. Payvandi, and A.L. Hansell Patterns of comorbidities in newly diagnosed COPD and asthma in primary care Chest 128 2005 2099 2107
28. M.V. Lopez Varela, M. Montes de Oca, R.J. Halbert, A. Muino, R. Perez-Padilla, and C. Talamo Sex-related differences in COPD in five Latin American cities: the PLATINO study Eur Respir J 36 2010 1034 1041
29. A. Sood, B.K. Dawson, W. Eid, L.E. Eagleton, J.Q. Henkle, and P. Hopkins-Price Obesity is associated with bronchial hyper-responsiveness in women J Asthma 42 2005 847 852
30. B.R. Celli, C.G. Cote, J.M. Marin, C. Casanova, M. Montes de Oca, and R.A. Mendez The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease N Engl J Med 350 2004 1005 1012